This article has been corrected. Please see J Manag Care Spec Pharm. 2023;29(5):569-75.
Atlas SJ, Kim K, Nhan, et al. Medications for obesity management: Effectiveness and value. J Manag Care Spec Pharm. 2023;29(5):569-75.
The authors would like to make the following correction:
As originally printed, the results in Table 2 for phentermine/topiramate were attributed to liraglutide, and results for liraglutide were attributed to phentermine/topiramate. The corrected table is shown below. The corresponding text in the body of the manuscript is correct as originally printed.
The corrected article is available online.
TABLE 2.
Network Meta-Analysis Results on Weight Loss Outcomes: Medications for Obesity Management vs Placebo
| Percent weight loss from baseline at 1 year | ≥5% Weight loss | ≥10% Weight loss | |
|---|---|---|---|
| Mean difference (95% CrI) | Odds ratio (95% CrI) | ||
| Semaglutide | −13.7 (−12.6 to −15.1) | 17.3 (8.9-38.3) | 22.4 (13.6-36.2) |
| Liraglutide | −5.0 (−3.9 to −6.1) | 4.3 (2.5 to 6.7) | 4.2 (2.6 to 5.7) |
| Phentermine/topiramate | −9.1 (−7.1 to −11) | 8.6 (3.3 to 22.0) | 8.8 (4.7 to 18.1) |
| Bupropion/naltrexone | −4.6 (−3.0 to −6.0) | 4.3 (1.7-10.2) | 3.6 (2.0-6.8) |
CrI = credible interval.